Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1444192/000095017022027060/acst-20221228.htm
March 2023
March 2023
February 2023
February 2023
January 2023
December 2022
November 2022
September 2022
March 2020
February 2020
February 2020
February 2020
February 2020
February 2020
January 2020
December 2019
November 2019
November 2019
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1444192/000095017022027060/acst-20221228.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Acasti Pharma Inc..
Acasti Pharma Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 8-K Corporate News
Ticker: ACSTEvents:
CIK: 1444192
Form Type: 8-K Corporate News
Accession Number: 0000950170-22-027060
Submitted to the SEC: Wed Dec 28 2022 8:10:55 AM EST
Accepted by the SEC: Wed Dec 28 2022
Period: Wednesday, December 28, 2022
Industry: Pharmaceutical Preparations